Cancer stage at diagnosis in patients infected with the human immunodeficiency virus and transplant recipients

Cancer

Volumn 121, Issue 12, 2015, Pages 2063-2071

  Shiels, Meredith S ^a   Copeland, Glenn ^b   Goodman, Marc T ^c   Harrell, Janna ^d   Lynch, Charles F ^e   Pawlish, Karen ^f   Pfeiffer, Ruth M ^a   Engels, Eric A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MICHIGAN DEPARTMENT OF COMMUNITY HEALTH   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d UTAH CANCER REGISTRY   (United States)

^e UNIVERSITY OF IOWA   (United States)

^f NEW JERSEY DEPARTMENT OF HEALTH AND SENIOR SERVICES   (United States)

Author keywords

cancer; human immunodeficiency virus (HIV); stage; transplant

Indexed keywords

ADULT; ANUS CANCER; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER RISK; CANCER STAGING; COLORECTAL CANCER; FEMALE; GRAFT RECIPIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOCOMPROMISED PATIENT; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; ORGAN TRANSPLANTATION; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; RISK REDUCTION; STOMACH CANCER; UNITED STATES; UTERINE CERVIX CANCER; ADVERSE EFFECTS; AGED; HISTOCOMPATIBILITY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MIDDLE AGED; NEOPLASMS; PATHOLOGY; PROCEDURES; VIROLOGY; YOUNG ADULT;

ADULT; AGED; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOSUPPRESSION; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; TRANSPLANT RECIPIENTS; TRANSPLANTATION IMMUNOLOGY; YOUNG ADULT;

EID: 84930384701     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29324     Document Type: Article

References (24)

1. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM,. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007; 370: 59-67.
2. Miao Y, Everly JJ, Gross TG, et al., De novo cancers arising in organ transplant recipients are associated with adverse outcomes compared with the general population. Transplantation. 2009; 87: 1347-1359.
3. Berretta M, Cappellani A, Di Benedetto F, et al., Clinical presentation and outcome of colorectal cancer in HIV-positive patients: a clinical case-control study. Onkologie. 2009; 32: 319-324. http://www.ncbi.nlm.nih.gov/pubmed/?term=Di%20Benedetto%20F%5BAuthor%5D&cauthor=true&cauthor-uid=19521118.
4. Chapman C, Aboulafia DM, Dezube BJ, Pantanowitz L,. Human immunodeficiency virus-associated adenocarcinoma of the colon: clinicopathologic findings and outcome. Clin Colorectal Cancer. 2009; 8: 215-219.
5. Brock MV, Hooker CM, Engels EA, et al., Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient care. J Acquir Immune Defic Syndr. 2006; 43: 47-55.
6. Shiels MS, Cole SR, Mehta SH, Kirk GD,. Lung cancer incidence and mortality among HIV-infected and HIV-uninfected injection drug users. J Acquir Immune Defic Syndr. 2010; 55: 510-515.
7. Sigel K, Wisnivesky J, Gordon K, et al., HIV as an independent risk factor for incident lung cancer. AIDS. 2012; 26: 1017-1025.
8. Yehia BR, Fleishman JA, Agwu AL, Metlay JP, Berry SA, Gebo KA,; HIV Research Network. Health insurance coverage for persons in HIV care, 2006-2012. J Acquir Immune Defic Syndr. 2014; 67: 102-106.
9. Denning P, DiNenno E,. Communities in Crisis: Is There a Generalized HIV Epidemic in Impoverished Urban Areas of the United States? Atlanta, GA: Centers for Disease Control and Prevention; 2014.
10. Walker GV, Grant SR, Guadagnolo BA, et al., Disparities in stage at diagnosis, treatment, and survival in nonelderly adult patients with cancer according to insurance status. J Clin Oncol. 2014; 32: 3118-3125.
11. Engels EA, Biggar RJ, Hall HI, et al., Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer. 2008; 123: 187-194.
12. Glueckert LN, Redden D, Thompson MA, et al., What liver transplant outcomes can be expected in the uninsured who become insured via the Affordable Care Act? Am J Transplant. 2013; 13: 1533-1540.
13. Shiels MS, Goedert JJ, Moore RD, Platz EA, Engels EA,. Reduced risk of prostate cancer in U.S. men with AIDS. Cancer Epidemiol Biomarkers Prev. 2010; 19: 2910-2915.
14. Preston-Martin S, Kirstein LM, Pogoda JM, et al., Use of mammographic screening by HIV-infected women in the Women's Interagency HIV Study (WIHS). Prev Med. 2002; 34: 386-392.
15. Rahangdale L, Sarnquist C, Yavari A, Blumenthal P, Israelski D,. Frequency of cervical cancer and breast cancer screening in HIV-infected women in a county-based HIV clinic in the Western United States. J Womens Health (Larchmt). 2010; 19: 709-712.
16. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H,; Centers for Disease Control and Prevention (CDC); National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009; 58: 1-207.
17. Suneja G, Shiels MS, Angulo R, et al., Cancer treatment disparities in HIV-infected individuals in the United States. J Clin Oncol. 2014; 32: 2344-2350.
18. Wells JS, Holstad MM, Thomas T, Bruner DW,. An integrative review of guidelines for anal cancer screening in HIV-infected persons. AIDS Patient Care STDS. 2014; 28: 350-357.
19. McDermott D, Lebbe C, Hodi FS, et al., Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat Rev. 2014; 40: 1056-1064.
20. Vajdic CM, van Leeuwen MT, Webster AC, et al., Cutaneous melanoma is related to immune suppression in kidney transplant recipients. Cancer Epidemiol Biomarkers Prev. 2009; 18: 2297-2303.
21. Zhang H, Chin AI,. Role of Rip2 in development of tumor-infiltrating MDSCs and bladder cancer metastasis. PLoS One. 2014; 9: e94793.
22. Babjuk M, Burger M, Zigeuner R, et al,; European Association of Urology. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013; 64: 639-653.
23. Brincks EL, Risk MC, Griffith TS,. PMN and anti-tumor immunity-the case of bladder cancer immunotherapy. Semin Cancer Biol. 2013; 23: 183-189.
24. van Rhijn BW, van Leenders GJ, Ooms BC, et al., The pathologist's mean grade is constant and individualizes the prognostic value of bladder cancer grading. Eur Urol. 2010; 57: 1052-1057.